ISC 2018: ARISE II Supports J&J's EmboTrap Stent-Retriever
The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.
You may also be interested in...
Johnson & Johnson has added the Embotrap clot retrieval device to its US offering after the product got FDA clearance. It will compete with Medtronic's Solitaire and Stryker's Trevo, which are already on the US market.
M&A deals rained down in April with the highest number of acquisitions of the year to date. The month saw 14 M&A deals, up by four from March's total, but still down from the 16 deals recorded in April 2016.
A pivotal trial of Stryker's Trevo, a device for removing clots in the blood vessels of ischaemic stroke patients, has met its primary endpoint, paving the way for US approval. Stryker plans to use the data from the study, TREVO 2, in a 510(k) application with the FDA; the firm previously told Clinica that it anticipates clearance in late 2012 or early 2013 (www.clinica.co.uk, 1 December 2011).